Abbott’s concussion-detecting blood test approved by FDA
March 8, 2023Medical Communications
US-based Abbott, a medical technology company, has received FDA approval for its laboratory blood test which detects traumatic brain injury …
Hospital for Special Surgery reveals 3D surface topographic scan for scoliosis patients
March 8, 2023Medical Communications
Researchers at New York City’s Hospital for Special Surgery (HSS) have found that using a 30-camera array, or 3dMD, can …
FDA grants de novo approval to Neuromod’s tinnitus device
March 8, 2023Medical Communications
The FDA has granted de novo approval to Neuromod’s Lenire device which includes Bluetooth headphones, a handheld controller and the …
Redx Announces RXC004 Topline Data From a Phase 2 Monotherapy Module
March 8, 2023Business Services
Alderley Park, UK, 8 March 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …
POLB 001 patent portfolio strengthened through granting of US patent
March 8, 2023Business Services
8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical …
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
March 7, 2023Business Services
Parma, Italy and Solna, Sweden, March 7th, 2023 – Chiesi Farmaceutici S.p.A (“Chiesi Group”) and Affibody AB (“Affibody”) today announced …
Funding to increase access to early phase clinical trials given to Yale Cancer Center
March 7, 2023Sales and Marketing
Yale Cancer Center has announced it has received collaborative funding aiming to support and increase access to early phase clinical …
Wearable sensor helps detect heart attacks
March 7, 2023Research and Development
RCE Technologies has developed a bracelet-like device that can measure levels of troponin-I in the patient’s blood, providing a more …
BioMarin receives FDA update for gene therapy for adults with severe haemophilia A
March 7, 2023Medical Communications
Global biotechnology company BioMarin Pharmaceutical has announced that it’s received an update from the FDA, detailing the extension of their …
Sooma receives FDA Breakthrough Device designation for depression therapy device
March 7, 2023Medical Communications
Finnish company Sooma Medical has received Breakthrough Device designation by the FDA for its portable, at-home neuromodulation device to treat …
Late-Breaking Phase 3 A DUE Data Show Investigational Single-Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Haemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)
March 6, 2023Business Services
BEERSE, Belgium, 6 March, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase …
Moderna chooses Oxfordshire for new UK facility
March 6, 2023Manufacturing and Production
US biotech firm Moderna has chosen Harwell Science Campus in Oxfordshire for its new UK R&D facility. The campus is …
Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device
March 6, 2023Medical Communications
Bristol Myers Squibb and Viz.ai, an AI-powered medical imaging company, have signed a deal to use AI to detect and …
Abbott announces positive clinical study data for both TriClip system and MitraClip therapy
March 6, 2023Research and Development
Abbott has announced positive data from two separate studies, which looked at its TriClip transcatheter edge-to-edge repair (TEER) system and …
Lilly receives approval for expanded indication for breast cancer therapy
March 6, 2023Research and Development
Following positive data from Eli Lilly’s phase 3 monarchE trial, the FDA has granted approval for the expanded indication for …
86% of pharma and biotech companies plan to invest in ‘digitally agile’ supply chains in the next 12 months
March 6, 2023Business Services
LONDON 6th March 2023 86% of pharma and biotech companies say they plan to become more digitally agile, according to …
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
March 3, 2023Business Services
Manchester, UK, 3rd March 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver …
Globesity: the silent pandemic of the 21st century. Multidisciplinary and new incisionless endoscopic technique may be an effective solution for adult patients.
March 3, 2023Business Services
London, 03/03/2023- Ahmed is 45 years old and weighed 120 kg. He was always very tired, and would even fall …
Elon Musk’s Neuralink rejected by FDA for human trials
March 3, 2023Medical Communications
The FDA has reportedly rejected a bid by Elon Musk’s Neuralink in which they proposed the initiation of human testing …
FDA grants orphan drug designation to Temferon for glioblastoma multiforme
March 3, 2023Medical Communications
The FDA has granted Temferon an Orphan Drug Designation (ODD) for use as a therapeutic option for patients with glioblastoma …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
